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ABSTRACT 
The purpose of this project was to answer the question: Is the administration of warfarin the best 
practice for prevention of stroke in the person who is over the age of 70 years, who has 
nonvalvular atrial fibrillation (NV AF), and who is at high risk for having a stroke? A 
comprehensive literature review was conducted to help answer the primary research question. 
The findings of this review demonstrated that the administration of warfarin therapy was the best 
practice for the prevention of strokes in high-risk populations. The literature presented in this 
project further identified that although research findings support the use of warfarin therapy as 
best practice for prevention of strokes in the high-risk population, warfarin therapy was highly 
underutilized in general practice or has been managed subtherapeutically. Eight factors that may 
have affected the prescribing practices or suboptimal use of warfarin therapy by the health care 
practitioners were discussed. The project also explored how nurse practitioners can offer 
solutions for optimizing warfarin therapy in NV AF patients and concluded with 
recommendations for how nurse practitioners may help optimize treatment for patients with 
NVAF. 
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CHAPTER 1 
INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in the general 
population. As the population ages, the incidence of AF increases dramatically. It is imperative 
that health care practitioners (HCPs), including family nurse practitioners (FNPs), particularly 
those in primary care settings, pay close attention to this condition so that early detection and 
prevention of complications of AF can become a priority. Within this paper, the term HCP refers 
to nurse practitioners (NPs) and physicians. With AF as a focus, strategies can be developed that 
will help the older population be as healthy as possible. The older population is the cohort that is 
most at risk for developing complications of AF. The focus of this paper, therefore, was on the 
patient who was over 70 years of age with nonvaluvular AF (NV AF). This age was selected 
because the majority of the studies on the treatment ofNVAF have an average age of 70 to 75. 
The prevalence ofNVAF in the general population is between 1-12% with the 
prevalence increasing with the aging population. In the aging population, pharmaceutical 
therapies that help to reduce risks, which are associated with having NVAF, are commonly 
underutilized or managed suboptimally (Schumann & Ewigman, 2007). Such practices · leave the 
aging person vulnerable to serious complications that are associated from having NV AF. The 
greatest risks of leaving NV AF untreated are cardiogenic shock, myocardial infraction, stroke, 
and death (Rao, Julka, & Paruchuri, 2009). To diminish these risks, optimal treatment of NV AF 
is critical (Rao et al., 2009). Therefore, treatment of NV AF is critical in order to mitigate these 
risks. Foremost among the risks are strokes. 
This project narrowed the focus to the best methods for prevention of strokes. According 
to the Canadian Stroke Strategy (Canadian Stroke Network & Heart and Stroke Foundation of 
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Canada, 201 0), the rate of ischemic strokes of all ages related to AF is one in six, and this 
increases to one in four in the octogenarian population (Rash et al., 2007). Age may play a factor 
in the risk for having a stroke but not all older persons are at high risk for having a stroke. The 
British Columbia (BC) Guidelines and Protocols Advisory Committee (2009) recommended that, 
prior to initiating stroke prevention therapies, HCPs complete a risk stratification tool to 
calculate the level of risk of a stroke for each patient with NV AF. 
The research conducted for this project identified that the administration of warfarin was 
the best practice for prevention of strokes for high-risk patients. Warfarin is a vitamin K 
antagonist that works by interfering with vitamin K metabolism and helps prevent the formation 
of a thrombus, which is the cause of many strokes (Baker et al., 2004; Murray, 2007). The key to 
stroke prevention is maintaining therapeutic warfarin levels by keeping the international 
normalized ratio (INR) levels between 2.0 and 3.0 (Fuster et al. , 2006; Gladstone et al., 2009), as 
this reduces the risk of thrombus formation. Despite these findings, the research further 
identified that warfarin therapy is significantly underutilized in the older adult population, who 
are at high risk of a stroke. In fact, most people over 75 years of age are either not prescribed 
warfarin or the warfarin therapy prescribed is at subtherapeutic levels (Gladstone et al. , 2009). 
Management of AF with warfarin requires careful management and considerable practitioner 
skills and time. Factors that may contribute to subtherapeutic case management ofNVAF 
patients ' and HCPs' decision to administer warfarin and maintain therapeutic levels are 
examined in Chapter 2 of this project. This project reviews the role of the HCP in relation to 
management of the warfarin therapy and offers strategies and areas of responsibility that the FNP 
can assume to optimize therapeutic use of warfarin therapy in patients with NV AF. Within 
interdisciplinary primary care teams NPs work autonomously and in collaboration with other 
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HCPs. FNPs provide holistic care for patients with an emphasis on health promotion and disease 
prevention and have a valuable role to play in optimizing health care for patients with NVAF. 
There are some patients with NV AF who are not appropriate candidates for anticoagulant 
therapy and alternative therapeutic choices other than warfarin therapy such as aspirin or 
dabigatran may be considered. It is important to note that the new drug called dabigatran, an 
oral-direct thrombin inhibitor, has been demonstrating promising results for preventing strokes as 
well and it may be more beneficial than warfarin (Connolly et al. , 2009) but more studies are 
needed. Dabigatran has a number of positive attributes in that it has a short half-life and it does 
not require laboratory monitoring, which may make it the priority thrombin inhibitor of the 
future (Connolly et al., 2009). This new drug is beyond the scope of this paper and, until more 
research is conducted to verify the benefits and contraindications of Dabigatran, warfarin therapy 
remains the mainstay treatment for the high-risk population. 
The purpose of this project is to answer the primary question: Is the administration of 
warfarin the best practice for prevention of stroke in the person who is over the age of 70 years, 
who has idea NV AF and who is at high risk for having a stroke? The question has been expanded 
into three subquestions: 
1. If warfarin therapy is the best practice for preventing strokes in the high-risk older 
population, is it being managed optimally? 
2. What factors contribute to suboptimal management ofNVAF patient and the 
administration of warfarin therapy? 
3. How can FNPs facilitate optimal administration of warfarin therapy? 
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To answer these questions, an integrative literature review was conducted and the 
findings are presented within the body of this project. The project begins by providing the 
background and context for the development of these questions. 
Background and Context 
Atrial Fibrillation 
The Population at the Highest Risk for Developing Atrial Fibrillation 
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There are almost 250,000 Canadians living with AF (Heart & Stroke Foundation ofBC & 
Yukon, 2011). The prevalence of AF increases with age and is more common in men than in 
women (Go et al., 2001). In the population under 60 years of age the AF rate is 1% (Fuster et al., 
2006), in the population over 60 years of age the rate increases to 4% (Rosenthal et al., 2011 ), 
and in populations over the age of 75 years the rate increases further to 12% (Canadian Stroke 
Network & Heart and Stroke Foundation of Canada, 2010). Although AF affects the entire 
population, the population that is advanced in age is at a higher risk of developing AF and 
suffering complications of the condition such as a stroke. According to the Statistics Canada 
(2011) census conducted in 2006, the number of people 65 years and over was 4.3 million, which 
is an increase of more than 11.5% over the last 9 years. Within this cohort, 25% or 1.3 million 
older adults were over 80 years of age (Statistics Canada, 2009). 
As the age of the population increases, more patients will potentially be at risk for 
developing NV AF. It is predicted that the number of patients with AF may double in future years 
(Gersh, Tsang, Barnes, & Seward, 2005). Therefore, screening the older population for AF needs 
to be considered a priority for the FNPs in primary care settings. FNPs who provide therapeutic 
care for patients with AF must have a broad knowledge base of AF. This section provides an in-
depth look at the definition of AF, the pathophysiology, associated risk factors, clinical 
manifestations, and the diagnostic process. 
Definition and Classification of Atrial Fibrillation 
11 
Normal sinus rhythm, which is the normal conduction pathway in the heart, begins with a 
single electrical impulse from the sinoatrial node. This impulse travels in a direct path to the 
atrioventricular (AV) node and completes its conduction in the ventricles. AF, on the other hand, 
is a supraventricular arrhythmia that, ifuntreated, is expressed through rapid (240-320 
beats/min) irregular electrical impulses that fire randomly and conduct in a disorganized and an 
uncoordinated pattern throughout the atria (Fuster et al., 2006). On an electrocardiogram (ECG) 
this uncoordinated activity is noted by the loss of P waves and the addition of rapid irregular 
oscillations or fibrillatory waves. The ventricular response to this random atrial activity depends 
on the status of the A V node and "other conducting tissues, vagal and sympathetic tone, the 
presence or absence of accessory pathways, and the action of drugs" (Fuster et al., 2006, p. 71 0). 
Ifthe A V node is functional the QRS complex may be narrow (Banner, 2008; Fuster et al., 
2006). 
Patients with the diagnosis of AF can be grouped into two categories: (a) valvular, which 
includes patients with a history of valvular disease such as rheumatic mitral valve disease, 
prosthetic heart valves or other valvular processes, as the underlying factors contributing to their 
AF; and (b) nonvalvular, which includes patients with all other contributing factors for AF. 
Valvular AF and NV AF have different pathophysiology and require different treatment 
protocols. The focus of this project shifted to patients with NV AF because they represent a larger 
portion of patients with AF, and the majority of the major research trials have been conducted on 
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patients with NV AF (Manning, Singer, & Lip, 2011 ). Patients with NV AF are most commonly 
seen in an HCP' s clinical practice and, therefore, represent a population that FNPs will care for. 
The following presents the terms and AF classification that have been defined by the 
American College of Cardiology/ American Heart Association/European Society of Cardiology 
(ACC/AHA/ESC): (a) recurrent AF is more than two episodes of AF, lasting more than 30 
seconds; (b) lone AF, which occurs in patients who are less than 60 years of age and those who 
are without electrocardiographic evidence of cardiopulmonary disease; (c) paroxysmal AF is 
usually brief, lasting less than 24 hours and can last up to 7 days, and it ends spontaneously; 
(d) persistent AF lasts longer than 7 days and requires either electrical or pharmaceutical 
conversion; and (e) permanent AF, sometimes called chronic AF, lasts for at least one year and 
remains permanent despite attempts to convert the rhythm back to normal sinus rhythm (Banner, 
2008; Fuster et al., 2006; Rao et al. , 2009). 
Pathophysiology and Contributing Factors 
The electrical chaos that is seen in the atria of patient with AF is not absolutely 
understood. However, it is clear that patients with AF have structural remodelling within the 
heart muscle. Fibrotic patches, fatty or other infiltration, or inflammation that affect the 
myocardium or nodes may individually or collectively play an active role in the physiological 
changes that contribute to AF (Aldhoon, Melenovsky, Peichl, & Kautzner, 2010; Fuster et al., 
2001). Further contributing factors may include oxidative stress injury, neurohormonal 
activation, and autonomic imbalance (Aldhoon et al., 2010). 
Associated Risk Factors of Atrial Fibrillation 
There are a number of conditions or risk factors that are associated with the development 
of AF (Banner, 2008 ; Fuster et al. , 2006; Gersh et al. , 2005 ; Go, 2005 ; Kellen, 2004; Rao et al. , 
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2009). Although not all patients with one or more of these risk factors will develop AF, there is a 
strong correlation between the risk factors and the development of AF. Screening patients who 
have risk factors commonly associated with AF may help early detection of AF and may help 
HCPs to initiate therapeutic interventions as early as possible, which subsequently may help to 
prevent negative patient outcomes such as strokes (Lip, 2009). The risk factors listed on the left-
hand side of Table 1 are factors that are more commonly seen in the primary health care setting, 
while those listed on the right-hand side present risk factors that may be more commonly seen in 
specialized settings. It is important to note that some patients (10-15%) may experience AF 
without having any underlying risk factors (Rosenthal et al., 2011). 
Table 1. 
Risk Factors Strongly Associated With Atrial Fibrillation 
Risk Factors Commonly Seen in Primary 
Health Care Setting 
Advanced age 
Congestive heart failure 
Coronary artery disease 
Diabetes mellitus 
Excessive alcohol and caffeine intake 
Fever 
Hypertension 
Hyperthyroidism 
Obesity 
Pneumonia 
Pulmonary diseases 
Sleep apnea 
Risk Factors Commonly Seen in a Specialized 
Care Setting 
Electrocution 
Hypertrophic cardiomyopathy 
Inflammation with elevated C-reative protein 
Myocarditis and Pericarditis 
Pulmonary embolism 
Surgery (most often cardiac related) 
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Clinical Manifestations of Atrial Fibrillation 
The most extreme clinical manifestations of AF are critical emergencies. Therefore, it is 
important to know the most common clinical manifestations. These include: palpitations, chest 
pain, dyspnea, fatigue, lightheadedness, or syncope, however, some patients are completely 
asymptomatic (Fuster et al. , 2006). Patients who are in rapid AF can quickly become 
haemodynamically unstable and present with signs of "cardiogenic shock, pulmonary edema, 
acute myocardial infarction, or unstable angina" (Rao et al. , 2009, p. 66) . Rapid assessment of 
such critical emergencies is important so that urgent transfer of care to an acute care setting can 
be facilitated quickly. 
Diagnosis of Atrial Fibrillation 
The diagnosis of AF is often identified during a routine physical or as a result of a patient 
presenting with symptomatic clinical manifestation of AF. Sadly, some patients do not receive 
the diagnosis of AF until after they have experienced a stroke. The irregular pulse is easily 
detected by radial or apical exam. Definitive diagnosis comes from the interpretation of the 12-
lead ECG. It is recommended that the reviewer pay special attention to wave form morphology, 
as AF may be confused with a number of other arrhythmias. Further, an extensive history and 
exam may be conducted including: medications review, tests such as a bolter monitor, chest 
x-ray, echocardiogram, and blood profile (Banner, 2008; Rao et al. , 2009). An important finding 
that came out ofHylek, Evans-Molina, Shea, Henault, and Regan' s (2007) trial was that 19% of 
the ::=: 80 years of age group who had a previous diagnosis of chronic AF had reverted back to 
sustained sinus rhythm. Hylek et al. 's finding raised an important point that those patients who 
are diagnosed with chronic AF may not necessarily remain permanently in this rhythm, and 
follow-up assessments can help determine if these patients remain in AF and identify if the 
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patient is still a candidate for stroke prevention therapy. Once the diagnosis of AF is made, the 
implications of this diagnosis, such as the potential for having a stroke, must be considered and a 
treatment plan developed. 
Stroke 
One of the greatest risks for untreated AF is stroke (Rao et al., 2009). Strategies for 
robust AF identification, treatment, and stroke prevention may help reduce the number of people 
who experience a primary or secondary stroke. Patients with chronic conditions such as a strokes 
or AF have a significant impact on our health care system (Canadian Institute for Health 
Information, 2011b). It is important that all health care team members increase their awareness 
of methods that provide optimal care and prevention of strokes. The following section provides a 
definition of stroke and examines the implications of this diagnosis. 
Definition and Implications of a Stroke 
An ischemic stroke occurs if a stasis precipitated thrombus is formed and blocks blood 
flow to the brain. This type of stroke represents 80% of all stroke diagnoses (Heart & Stroke 
Foundation ofBC & Yukon, 2011). A haemorrhagic stroke occurs when a blood vessel ruptures 
in the brain causing cells to die (Heart & Stroke Foundation ofBC & Yukon, 2011). In NV AF 
patients, thrombus formation is most commonly found in the left atrial appendage and is induced 
by the combination of turbulent and stagnant blood flow, resulting from the uncoordinated atrial 
activity and platelet aggravation and hypercoagulabi1ity (Banner, 2008; Fuster et al. , 2006). 
In Canada, every 10 minutes someone suffers a haemorrhagic or ischemic stroke, and 
15% ofthese strokes are attributed to AF (Heart & Stroke Foundation, 2011). Patients who do 
not receive treatment have a 5% chance per year of having an ischemic stroke (Albers et al., 
2001; Heart & Stroke Foundation ofBC & Yukon, 2011). In the Framingham Heart Study, 
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patients who were between the ages of 80 and 89 years and who were left untreated with AF had 
a 23.5% risk of having a stroke each year (Fuster et al., 2006). A person with AF who has a 
stroke will have more severe outcomes than an individual who has a stroke and does not have AF 
(Gladstone et al., 2009). Fifty percent of the people who had their first stroke related to AF will 
die within one year (Gladstone et al., 2009). These statistics reflect indirect cost at a community 
level and on the provincial health care budget. For patients with NV AF, the greatest independent 
risk factors for stroke are "prior thromboembolism, HF [heart failure], hypertension, increasing 
age, and diabetes mellitus" (Fuster et al., 2006, p. 722). The importance of early diagnosis, 
screening for risk factors, and excellent AF management is vital for preventing strokes and may 
help reduce health care expenditures in the long run. 
Treatment Choice: Clinical Practice Guidelines and Risk Stratification Tools 
Making the diagnosis of AF is the crucial first step in optimizing patient health care. The 
next most important step for preventing strokes is to initiate treatment to manage risk and 
prevent stroke. Deciding which treatment to initiate can be complex and complicated. However, 
clinical practice guidelines and risk stratification tools can help guide FNPs to make the best 
treatment choice. 
Clinical Practice Guidelines 
There are two major guidelines for HCPs in BC to follow: the British Columbia Clinical 
Practice Guidelines (Government of British Columbia, Ministry of Health [BC Ministry of 
Health], n.d.b) and the Canadian Cardiovascular Society's (20lO)Atrial Fibrillation Guidelines. 
The BC guideline (Guidelines and Protocols Advisory Committee, 2009), supported by the BC 
Minister of Health, provides HCPs with comprehensive guidelines to care for all types of patient 
concerns. Within the general BC guidelines, HCPs who are caring for a person with NV AF can 
...... 
•••••• > 
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access the BC's Stroke and Transient Ischemic Attack- Management and Prevention guideline 
(Guidelines and Protocols Advisory Committee, 2009) and the Warfarin Therapy Management 
guideline (Guidelines and Protocols Advisory Committee, 2010) for medical case management 
recommendations . The BC guidelines provide clear and concise recommendations to the HCP 
for administration of warfarin therapy and prevention of strokes. The focus of the BC guidelines 
are not specific to atrial fibrillation and do not provide comprehensive care guidelines for 
patients with NVAF. The Canadian Cardiovascular Society's (2010) Atrial Fibrillation 
Guidelines help to fill this gap and provide the HCP with recommendations that focus on the 
broader care needs of the NV AF patient. Both the BC and the Cardiovascular Society guidelines 
are current and evidenced based (BC Ministry of Health, n.d.b; Canadian Cardiovascular 
Society, 2010), and both guidelines recommend that the HCP complete the CHADS2 (Cardiac 
failure, Hypertension, Age, Diabetes, Stroke) risk stratification assessment tool to determine the 
level of stroke risk and to provide recommendations for determining the appropriate 
antithrombus protocol. 
Risk Stratification Tools 
Risk stratification tools are not always straightforward, and the defining factors within 
the tool may not always reflect the actual patient' s risk for having a stroke. In saying this, risk 
stratification tools provide the HCP with a foundation to begin the assessment process so that 
patients who are at risk of having a stroke can be identified early on the health care continuum. 
With early identification, risk stratification tools can highlight patients who will benefit from 
therapeutic treatment options such as warfarin administration. The administration of warfarin 
brings along with it the risk of adverse effects of the drug and, therefore, not all patients require 
warfarin therapy. Risk stratification tools can help balance the risk-benefit ratio of such a 
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therapeutic choice. Risk stratification tools further help by creating a consistent screening 
process for all NV AF patients, which may help to reduce the risk of a patient possibly being 
overlooked or considered at a lower risk for a stroke than they may actually be (Chia, 2011). 
There are a number of different risk stratification tools used internationally. However, the 
most common tool for determining the patient's risk for having a stroke is the CHADS2 tool (BC 
Ministry of Health, 2009a). As shown in Table 2, a single point is allocated for each criterion 
that the patient meets, and two points are allocated if the patient has had a prior stroke. Once the 
total score has been calculated the HCP considers the treatment guidelines that align with the 
overall score (BC Ministry ofHealth, 2009b). 
Table 2. 
Cardiac failure, Hypertension, Age, Diabetes, Stroke (CHADS2) Tool 
Criteria Points 
C - Recent cardiac failure 
H - Hypertension 
A -Age 75+ 
D- Diabetes 1 
S - Prior stroke or transient ischemic attack 2 
Note. From Appendix A: Stroke risk assessment in atrial fibrillation: CHADS2 score (p. 1 ), by 
the Government of British Columbia, Ministry of Health Services, 2009, Victoria, BC, Canada: 
Author. Copyright 2009 the Government of British Columbia. 
To prevent strokes, the CHADS2 tool recommends the administration of aspirin for those 
patients who are at low risk for having a stroke, aspirin or warfarin therapy for individuals who 
are at moderate risk, and warfarin for those patients who are at high risk of having a stroke. See 
Table 3 for the treatment recommendations based on the CHADS2 score. 
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Table 3. 
Treatment Recommendations Based on CHADS2 Score 
CHADS2 Score Treatment Recommendation* 
0 ASA alone 
1 ASA or Warfarin (INR 2-3) 
2+ Warfarin (INR 2-3) 
Note. ASA = acetylsalicylic acid or aspirin; INR = international normalizing ratio. *These 
treatment recommendations can be made because, statistically, the probability of benefit appears 
to exceed the probability of harm. 
From Appendix A: Stroke risk assessment in atria/fibrillation: CHADS2 score (p. 1), by the 
Government of British Columbia, Ministry of Health Services, 2009, Victoria, BC, Canada: 
Author. Copyright 2009 the Government of British Columbia. 
Patients who are assessed (by the risk stratification tool) to be in the high-risk category 
for having a stroke are recommended to have the HCP initiate warfarin therapy. However, the 
use of age as a defining risk factor for determining the therapeutic choice to initiate warfarin 
therapy can influence the treatment protocols. Schumann and Ewigman (2007) identified that 
some practitioners and guidelines use 75 years of age as a moderate risk factor, such is the case 
with the CHADS2 (BC Ministry of Health, 2009a). Other risk stratification tools such as the 
American College of Chest Physicians tool use 75 years of age as a high risk factor (Singer et al., 
2008). 
Although the Government of BC recommends that FNPs use the BC guidelines (BC 
Ministry of Health, n.d.b), which direct the use of the CHADS2 tool (BC Ministry ofHealth, 
2009a), having an awareness of other existing risk stratification tools has merit. Another risk 
stratification tool that presents a slightly different approach to risk stratification than the 
CHADS2 tool is found in the A CCI AHA/ESC 2006 Guidelines for the Management of Patients 
with AF (Fuster et al., 2006). This ACC/AHA/ESC tool can be found in Figure Al in Appendix 
A. One other tool worth mentioning is the CHAzDSzVASc tool (Camm et al., 2010), which was 
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created by the European Society of Cardiology (ESC) and appears to provide even greater clarity 
for risk stratification that the CHADS2 tool. The explanation for the abbreviation 
CHAzDSz V ASc and tool can be found in Figure B 1 in Appendix B. Awareness of different 
stratification tools is pertinent so that the decision to choose one tool over another is grounded in 
the broader knowledge that the choice of one tool over another can influence the treatment 
protocols. 
Warfarin and the International Normalized Ratio 
The CHADS2 tool recommends that HCPs administer warfarin therapy for stroke 
prevention for patients who are at high risk of having a stroke (BC Ministry of Health, 2009a). 
Warfarin is a vitamin K antagonist, and it belongs to the coumarins drug class. Warfarin works 
by interfering with vitamin K metabolism, inhibiting synthesis of factors II, VII, IX, X, and the 
anticoagulant proteins C and S (Baker et al., 2004; Murray, 2007). There are a number of 
contraindications that indicate when warfarin should not be prescribed to patients, and these need 
to be considered during the assessment process prior to initiating warfarin therapy. The BC 
guidelines and protocols advisory committee directs HCPs to review the contraindication list and 
the risk factors for bleeding list; the HCP is asked to consider if the risk of bleeding outweighs 
the benefit of the therapy. These lists are identified in Figures Cl and C2 (see Appendix C). The 
key to best practice with the administration of warfarin is achieved by maintaining warfarin at 
therapeutic levels, which subsequently provides the patient with the best chance for the 
prevention of stroke. 
The INR is a blood test that was established to provide standardization of the 
prothrombin (PT) test. The INR test helps to determine if the warfarin has reached and remains 
within therapeutic levels for the patient. The INR test is formulated by taking the patient's PT 
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and dividing it by the mean normal PT (Garcia-Alamino et al., 2010). This ratio is then 
calculated using the conversion factor or International Sensitivity Index, which the World Health 
Organization established as a standard (Garcia-Alamino et al., 2010). The literature reviewed for 
this project acknowledged the importance of keeping the INR level within optimal therapeutic 
range when treating NV AF patients with antithrombotics prophylactically. After reviewing one 
provincial guideline, Warfarin Therapy Management (Guidelines and Protocols Advisory 
Committee, 2010), and three national guidelines-Canadian Cardiovascular Society's (2010) 
Atrial Fibrillation Guidelines, European Society of Cardiology's Guidelines for the Management 
of Atrial Fibrillation (Camm et al., 2010), the American, ACCIAHAIESC Practice Guidelines 
(Fuster et al., 2006)-it is clear that the INR target is 2.5 and the acceptable range for treating 
patients with NVAF is an INR level between 2.0 to 3.0. 
Summary 
In summary, this chapter identified that NV AF is commonly seen in primary care 
practices and if left untreated one risk of the NV AF is stroke. Stroke prevention in patients with 
NV AF must be the primary focus of HCPs. Clinical practice guidelines and risk stratification 
tools are available to help provide HCPs identify patients who are at risk of a stroke, stratify 
patients' level of risk, and provide recommendations for care for patients with NV AF. Fallowing 
the administration of a risk stratification tool, the stratification process can identify patients who 
are at low, moderate, or high risk of having a stroke. For patients who are at high risk of having a 
stroke, the best practice for stroke prevention is the administration of warfarin therapy. 
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CHAPTER2 
ANALYSIS OF THE LITERATURE 
This literature review was conducted to answer the main project question: Is the 
administration of warfarin the best practice for prevention of stroke in the person, who is over 
the age of70 years, who has NV AF, and who is at high risk for having a stroke? The question 
has been expanded into three subquestions: 
1. If warfarin therapy is the best practice for preventing strokes in the high-risk older 
population, is it being managed optimally? 
2. What factors contribute to suboptimal management of NV AF patient and the 
administration of warfarin therapy? 
3. How can FNPs facilitate optimal administration of warfarin therapy? 
Literature Search Strategy 
The main project question and subquestions 1 and 2 are discussed in this chapter and 
subquestion 3 is answered in the next chapter. Research reports and materials were gathered by 
accessing the University of Northern British Columbia's library and searching within the 
following search engines: Cumulated Index ofNursing and Allied Health Literature, Medline 
Full Text, Cochrane Database of Systematic Reviews, and Google Scholar. Databases were 
searched using the parameters provided in Appendix D. Reference lists of the literature cited 
were used to direct additional searches, and these findings were included within the overall 
literature review. The number of articles resulting from the search and a flowsheet identifying 
how the articles were then filtered and accepted for this project are provided in Appendix E. 
Inclusion criteria selected for articles published by authors who lived in Canada, the 
United States of America, the United Kingdom, Europe, and Australia. These articles were 
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included as similar health care standards exist in each of these regions and provided relevance to 
Canadian standards. The search was limited to literature published from 2001 to 2011 to ensure 
that all findings were current and relevant to contemporary practice. A few older studies were 
included in the project as they provided foundational information, which remains relevant today. 
The search was also limited to literature that was written in the English language and included 
information relating to patients who were 70 years of age or more and who had NV AF. The 
Department of Justice Canada (2009) defined older persons as individuals who are over age 65 
years. However, the age criterion for this project was increased to 70 years of age or older 
because the pertinent research used within the research findings section had inclusion criteria set 
at between 70 to 75 years for their study samples. As previously noted, NV AF was also a prime 
focus of this project. Literature that was not in English, literature that did not include patients 
with NV AF, literature conducted prior to 2001, and literature that focused on stroke prevention 
treatment that did not include warfarin therapy were excluded from the literature search. 
Findings 
As the rate of AF rises, HCPs require a thorough understanding of best practice for stroke 
prevention, which is one of the main risk factors of this diagnosis. Despite warfarin therapy 
being identified in research as the best practice for stroke prevention in the high-risk population, 
it is often not initiated or is managed subtherapeutically (Gladstone et al. , 2009). This section 
presents research evidence that demonstrates that warfarin is the best practice and that warfarin 
therapy has not been managed optimally. It concludes by identifying factors that may contribute 
to suboptimal case management. The research findings have been grouped into three sections: 
research that evaluates the use of warfarin, the problem of optimal warfarin management, and the 
reasons for suboptimal management of anticoagulation. 
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Research that Evaluates the Use of Warfarin 
This section of the paper presents trial findings that help to answer the study question: Is 
the administration of warfarin the best practice for prevention of stroke in the person who is over 
the age of 70 years, who has NV AF, and who is at high risk for having a stroke? Preventing 
strokes in the elderly population must be the principal goal of caring for patients with AF. 
Numerous research studies have been conducted on patients who have AF in an effort to 
understand best practice for prevention of thrombus and potential subsequent stroke (Dhond, 
Michelena, & Ezekowitz, 2003; Hart, Benavente, McBride, & Pearce, 1999; Gage, Fihn, & 
White, 2001; Halperin, 2005; Hart, Pearce, & Aguilar, 2007; Mant et al., 2007; Rash et al., 2007; 
van Walraven et al., 2002). 
Meta-analysis 
Two meta-analyses provide evidence to support the use of warfarin as best practice for 
prevention of strokes in patients with AF. Van Walraven et al. 's (2002) meta-analysis pooled 
data from six published trials and included a combined total of 4,052 adult patients who had been 
randomly assigned to oral anticoagulant or aspirin with or without anticoagulant and were 
followed for 1.9 years. Although the criteria included all ages of adults, the mean age was 71.7 
years old. Persons with permanent AF accounted for 67% of the entire population, and 65% of 
the population in this analysis had a high risk for having a stroke (van Walraven et al., 2002). 
The findings from van Walraven et al. 's analysis concluded that the risk of stroke was 
significantly lower in the oral anticoagulant group compared to the aspirin group (2.4 vs. 4.5 
events per 100 patient-years). The absolute risk reduction in the low-risk group was 0.4%, while 
in the high-risk group it was 3.3% (van Walraven et al., 2002). These results support the use of 
warfarin therapy as the best treatment for prevention of strokes in the high-risk population but 
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highlight the importance of risk stratification. The participants who were taking warfarin in this 
meta-analysis had almost double the chance of experiencing a major bleed than those who 
received aspirin (2.2 vs. 1.3 events per 100 patient years). This is concerning, however, in 
analyzing van Walraven et al. 's findings, although nine patients would experience a bleed over a 
period of a year, this risk is outweighed by the fact that if the HCP prescribed warfarin to 1,000 
patients during the same time frame the HCP would be able to prevent 23 ischemic strokes. 
One limitation to van Walraven et al.'s (2002) research was that it included a large 
number (1,215) of patients from the SPAF III trial, who were taking a combination of low-dose 
warfarin with aspirin at the same time. Combination therapy could have affected the findings, 
however, van Walraven et al. resolved this conflict by removing patients who had been on the 
combination therapy and conducted the study a second time. The trial was rerun including the 
remaining 2,837 patients; interestingly, the results barely changed (2.4 in those taking warfarin 
vs. 3.8 in those taking aspirin) and warfarin remained the superior choice for prevention of 
strokes. Although the overall findings support the use of warfarin, the relative benefit of warfarin 
therapy compared to aspirin for prevention of strokes was higher in the under 75 year old 
population compared to the over 75 year old population (p for interaction= .08). However, the 
risk of bleeding did not change between the two age groups (van Walraven et al., 2002). 
The second meta-analysis conducted by Hart et al. (2007) compared aspirin and warfarin 
for pharmaceutical treatment in prevention of a stroke in patients. This analysis included the six 
trials that were part of the van Walraven et al. (2002) meta-analysis. The strength of this analysis 
was that it was a much larger study, including 29 randomized trials with a combined total of 
28,044 patients with NV AF. The analysis included studies that were conducted between 1966 
and 2007. The results were significant and showed that warfarin reduced strokes by 60% while 
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antiplatelets reduced the risk strokes by 20% (Hart et al., 2007). The results of this meta-analysis 
further demonstrated that warfarin produced a 25% reduction in the death rate when compared 
with patients who had no antithrombotic treatment (Hart et al., 2007). In support of warfarin as 
the best practice for prevention of strokes, this meta-analysis demonstrated that the risk of 
haemorrhage was less than the absolute reduction in strokes. Although Hart et al. 's meta-analysis 
identified that the rate of intracranial haemorrhage doubled with the use of warfarin (when 
compared to aspirin), the absolute risk increase was low at 0.2%. This meta-analysis added to the 
literature that supported the use of warfarin in prevention of strokes (van Walraven et al., 2002). 
One limitation to consider in regards to risk ofbleeding was that most of the population within 
Hart et al. 's meta-analysis was already taking warfarin prior to participating in the studies. The 
first 90-days transition period, which puts the patient at the highest risk for a having a bleed 
(Hylek et al., 2007), was avoided. Consequently, these findings might be higher if the population 
was different. 
A second limitation to this project is that Hart et al. 's (2007) study included patients of 
any age, but the average age was 70 years old. Hart et al. acknowledged that age was the greatest 
risk for bleeding. This study focused on the younger older adult, and Hart et al. acknowledged 
that they were not confident that their study findings would be identical for the octogenarian 
population. Additionally, the patients included in Hart et al. 's meta-analysis were generally 
healthy, independent, and 62% of the study patients were male. Although this statistic is 
representative of the fact that more men than women develop AF (Rosenthal et al., 2011), Hart et 
al. 's results may not fairly represent the same outcomes for the female population. As the BC 
population ages, it is important to consider the ramification of age when calculating the bleeding 
risk and it may also be important to question if male and female patients have the same response 
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to warfarin therapy. Further, Hart et al. ' s study sample may not be reflective of the more 
complex and less independent patients the HCPs might see in their practice today. 
The limitations to both van Walraven et al. ' s (2002) and Hart et al. 's (2007) meta-
analyses included trials that had target INRs that varied between 2.0 and 4.2. Four of the six 
trials included in van Walraven et al. ' s analysis, which were also included in the Hart et al. 's 
analysis, had INRs over the optimal2.0-3.0, which could have contributed to some of the bleeds 
found in van Walraven et al. ' s study. Both meta-analyses included a mix oftrials that were 
conducted in both the primary care settings and acute care settings (Hart et al., 2007; van 
Walraven et al., 2002). Warfarin initiated and managed in the acute care settings may not be 
reflective of general practice, as environmental factors and strict INR controls are in place. It is 
important to consider trials that reflect the primary care setting, as this is more reflective of the 
majority of the settings that older adults will receive warfarin therapy. Mant et al. (2007) 
supported this idea, and their trial and Rash et al. ' s (2007) trial presented findings that focused 
on primary care settings. 
Single Trials 
One single trial that was not included within Hart et al.'s (2007) and van Walraven et 
al. 's (2002) meta-analyses provided further evidence to support the meta-analyses conclusion 
that warfarin was best practice for preventing strokes in the elderly with AF. The Birmingham 
atrial fibrillation treatment of the aged study (BAFTA) was conducted in England and Wales 
between 2001 and 2004 (Mant et al. , 2007). The 973 eligible patients included in the BAFTA 
trial were all 75 years of age and older (Mant et al. , 2007). Patients were randomly assigned to 
either take aspirin (75 mg/day) or dose-adjusted warfarin (Mant et al. , 2007). The INR was kept 
between 2.0-3.0 with the target INR at 2.5 (Mant et al. , 2007). 
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The strength ofMant et al. 's (2007) trial is that it provided evidence based on a primary 
care setting rather than a hospital or controlled environment. The primary care provider assessed 
patients every 6 months, and INR testing was conducted as per the primary care provider's usual 
practice (Mant et al., 2007). There were 24 primary events (21 strokes and 2 intracranial 
haemorrhages) in the warfarin group and 48 primary events in the group taking aspirin (Mant et 
al., 2007). The BAFTA trial demonstrated that warfarin was safer and more effective than aspirin 
in preventing strokes (Mant et al., 2007). Mant et al. reported that patients assigned to the 
warfarin arm of the trial had a lower yearly risk of intracranial ( 1. 8%) and extracranial (1.4%) 
haemorrhage than those taking aspirin (3.8% and 1.6% respectively). The overall yearly risk of a 
major bleed in BAFTA was 2% (Mant et al., 2007). Mant et al. 's trial demonstrated that age was 
not a contraindication for taking warfarin. For all age groups warfarin had the same risk of major 
haemorrhage, death, hospitalizations related to a nonstroke vascular event, or increase the 
mortality when compared to those patients taking aspirin. Among patients over 85 years of age 
who were on warfarin there was a 27% less chance of a major haemorrhage (Mant et al., 2007), 
which was interesting because few trials, including Hart et al. 's (2007) and van Walraven et al. 's 
(2002) meta-analyses, have been able to isolate the very old population and assure the HCP that 
the haemorrhage risk was low. More trials that target research on this population are needed to 
provide the HCP with increased confidence that their patients are at a low risk of experiencing a 
bleed when on warfarin therapy. 
Rash et al. (2007) conducted a trial testing the efficacy and safety of warfarin against 
aspirin for stroke prevention in octogenarians with AF (W ASPO). Although the W ASPO trial 
was included within Hart et al. 's (2007) meta-analysis and although it was not large enough to 
generalize to all octogenarians, the strength of Rash et al. 's trial was that it helped to fill the gap 
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in predicting outcomes in the octogenarian population and it provided evidence based on primary 
care settings. In 2006, the W ASPO trial, conducted in the United Kingdom, included persons 
who were between 80 and 90 years of age (Rash et al., 2007). In Rash et al. 's trial, 36 patients 
were randomized to receive dose-adjusted warfarin (INR between 2.0-3.0) and 39 patients 
received aspirin 300 mg/day. All patients were ambulatory and had permanent AF (Rash et al., 
2007). Patients were followed for one year, with assessments completed every 3 months in 
primary care settings. 
One limitation was that Rash et al. 's study was a small trial, with only 75 patients. 
However, this trial was able to significantly demonstrate that adjusted-dose warfarin was far 
superior to aspirin, having fewer adverse side effects (6% vs. 33% respectively) in the over 80-
year-old population. Rash et al. 's study also excluded patients who had previously been on 
warfarin. Therefore, the risk of bleeding results would not have reflected the first 90 days of 
warfarin therapy, which is the highest risk period for bleeds (Hylek et al., 2007). Another 
limitation to Rash et al. 's study was that it prohibited participation of any elder who had fallen 
once within 12 months of the study. Although this exclusion criterion reflects safety concerns for 
the patient's risk of potentially falling and having a bleed, it may have resulted in a study 
population that was not reflective of the general population. I was unable to find studies that 
predicted the outcome for a patient who fell one or two times in a year, continued to be at high 
risk of a stroke, and chose to accept the risk of warfarin therapy. It raises the question, how many 
falls (if any) are too many to benefit from receiving warfarin therapy? Future research might 
consider exploration of this question. 
A third single trial, the stroke prevention in atrial fibrillation (SP AF II) trial, also 
included within both Hart et al.'s (2007) and van Walraven et al.'s (2002) meta-analyses, 
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supported the use of warfarin as best practice for stroke prevention. The SP AF II trial was 
conducted in the United States over a period of 2.3 years and demonstrated that the benefit of 
dose-adjusted warfarin was the most effective treatment for preventing strokes in patients with 
AF (Halperin, 2005; "Warfarin Versus Aspirin," 1994). The SPAF II trial compared the 
effectiveness of warfarin and aspirin in two groups of patients: 715 patients who were under the 
age of 7 5 years of age and 3 85 patients who were over 7 5 years of age (Halperin, 2005; 
"Warfarin Versus Aspirin," 1994). After 3 years, the SPAF II trial found warfarin to be mildly 
more effective than aspirin (Halperin, 2005). The primary event rate in the group of participants 
over 75 years of age was 3.6% with warfarin and 4.8% with aspirin. However, the over 75 years 
of age cohort who received warfarin had a 1.8% per year risk of intracranial haemorrhage 
(Halperin, 2005). Although the SPAF II study demonstrated that the benefit of warfarin therapy 
outweighed the aspirin therapy for prevention of strokes, it concluded that the risk for bleeding in 
the older population needs to be carefully considered in the decision-making process for 
initiating warfarin ("Warfarin Versus Aspirin," 1994). 
The fourth single trial that supported warfarin therapy as best practice for prevention of 
strokes in the high risk population was the SPAF III trial, which enrolled 1,044 patients with AF, 
including 523 high-risk participants (Gage et al., 2001 ). Gage et al. 's (200 1) SP AF III trial 
evaluated if combining 325 mg aspirin with a low fixed-dose warfarin (INR target 1.2-1.5) 
would demonstrate beneficial outcomes compared to dose-adjusted warfarin (INR target 2.0-
3.0). The trial was stopped after 1.1 years when significantly higher rates of ischemic stroke and 
systemic embolization (7.9% vs. 1.9%) occurred in the combined group (Dhond et al., 2003). 
SP AF III concluded that combination therapy showed no therapeutic benefit and dose-adjusted 
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warfarin therapy was more effective for the patient without causing increased haemorrhagic 
complications (Dhond et al., 2003; Halperin, 2005; Hart et al., 2007). 
In summary, two meta-analyses and four single studies were reviewed to answer the 
study question. The conclusion drawn from these studies was that the administration of warfarin 
was the best practice for prevention of stroke in the person who is over the age of 70 years, who 
has NVAF, and who was at high risk for having a stroke (Dhond et al., 2003; Halperin, 2005; 
Hart et al., 2007; Mant et al., 2007; Rash et al., 2007; van Walraven et al., 2002; "Warfarin 
Versus Aspirin," 1994). Stroke prevention in patients with NV AF is paramount, and the optimal 
management of warfarin therapy must be in the forefront of FNPs minds. 
The Problem of Optimal Warfarin Management 
This section answers the study subquestion: If warfarin therapy is the best practice for 
preventing strokes in the high-risk older population, is it being managed optimally? Despite 
guidelines and research recommendations consistently identifying the importance and efficacy of 
warfarin management in older persons who are at high risk of a stroke, numerous research results 
identify that the majority of patients are not prescribed anticoagulation therapy by the HCP or 
that anticoagulation therapy has been initiated but remains subtherapeutic (Dhond et al. , 2003; 
Gattelari, Worthington, & Zwar, 2008; Gladstone et al., 2009; Tulner et al., 2010). Consequently, 
despite the literature stating that warfarin is the best drug therapy for many patients (Dhond et 
al., 2003 ; Halperin, 2005; Hart et al., 2007; Mant et al., 2007; Rash et al., 2007; van Walraven et 
al., 2002; "Warfarin Versus Aspirin," 1994), there seems to be a gap between best practice 
recommendations and HCPs' practice. The following section will present research findings that 
highlight the fact that the majority of patients are not adequately anticoagulated. The focus of 
this section will be on the role of the HCP in suboptimal warfarin use and not on the patient's 
role. The goal of this section is to identify suboptimal areas of practice so that strategies for 
FNPs to improve therapeutic use of warfarin therapy could be identified. 
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Research findings that identify reduced warfarin administration rates are not new. Over 
10 years ago Go et al. (1999) conducted the "Warfarin Use Among Ambulatory Patients with 
Nonvalvular Atrial Fibrillation: AnTicoagulation and Risk Factors in Aria! Fibrillation 
(ATRIA)" study. The ATRIA study was conducted between 1996 and 1997 and included 11,082 
people of all ages with NV AF in a large medical outpatient clinic setting (Go et al. , 1999). In Go 
et al. 's study evidence of AF was confirmed via ECG 80% of the time. Interestingly, 
confirmation of AF with ECG technology was not completed in some of the other studies 
reviewed for this project. Of the participants who had no known contraindications and who could 
have been candidates for warfarin therapy, only 55% were prescribed warfarin and for 
participants 85 years of age or older the percentage dropped to 35.4% (Go et al. , 1999). A few 
years later, Burton, Hamilton, Isles, and Norrie's (2001) study found similar low prescribing 
rates ofwarfarin. Burton et al. ' s study involved 30 primary care practices and included 858 
patients with NV AF who were considered appropriate candidates for warfarin. Within Burton et 
al. 's (2001) study the researchers found only 36.2% of the 858 patients were prescribed warfarin. 
Schumann and Ewigman (2007) added to these findings by evaluating the administrative practice 
of warfarin; they also focused on the person who was over 7 5 years of age person with NV AF. 
Similarly, Schumann and Ewigman' s research found that only 50% of eligible participants were 
prescribed anticoagulants. 
Ten years later, research continues to demonstrate that warfarin therapy remains 
underutilized despite research demonstrating it is best practice. Gladstone et al. (2009) studied 
597 patients who experienced a primary stroke and 323 patients who experienced a secondary 
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stroke prior to admission to one of 12 stroke centres in Ontario between 2003 and 2007. All 
study participants were over the age of 7 5 years and were known to have NV AF. After reviewing 
hospital records, Gladstone et al. reported their concern that older persons with NV AF appeared 
to be managed subtherapeutically in the community. Of the patients who were eligible for 
warfarin therapy on admission, Gladstone et al. found 40% of patients were prescribed warfarin, 
30% were prescribed aspirin, and 29% had no antithrombotic. Most importantly, 75% of those 
taking warfarin had subtherapeutic INR levels on admission, and only 10% of the overall 
population in the study with known AF were therapeutically anticoagulated (Gladstone et al., 
2009). 
There were three main limitations to Gladstone et al. 's (2009) study. First, the researchers 
did not have access to the patient history regarding reasons why patients may not have been 
prescribed warfarin. Second, the AF diagnoses were confirmed by a review of each patient's 
medical history records and were not confirmed by ECG. Third, the American College of Chest 
Physicians risk stratification tool was used (Singer et al., 2008), which automatically places 
patients in the high risk category if they are over 7 5 years of age. This is different from the 
CHADS2 tool (BC Ministry ofHealth, 2009a), which BC HCPs use today. In Gladstone et al.'s 
study, HCPs using the American College of Chest Physicians risk stratification tool (Singer et 
al., 2008) may not have classified some of the patients as being high risk or requiring warfarin 
therapy, which would lower the patient's eligibility criteria for this study. All studies I reviewed 
concluded patients who were at high risk of having a stroke were not being optimally prescribed 
warfarin therapy or had been managed subtherapeutically (Burton et al., 2001; Dhond et al., 
2003; Gattelari et al., 2008; Gladstone et al., 2009; Go et al., 1999; Schumann & Ewigman, 
2007; Tulner et al., 20 10), which increases the risk to these older persons for having a stroke. 
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Reasons for Suboptimal Management of Anticoagulation 
This section answers the subquestion: What factors contribute to suboptimal management 
ofNVAF patient and the administration of warfarin therapy? NVAF patients may not receive 
warfarin therapy for reasons such as allergies or the patient having other contraindications. 
However, there are cases in which HCPs overlooked a potential candidate for therapy. Research 
identifies that warfarin is best for prevention of strokes in high-risk persons, so why do we 
continue to see a significant number of patients not started on warfarin therapy or managed 
subtherapeutically? Is this an intentional omission of warfarin therapy, or is there further critical 
information obtained by the HCP that is not recognized in the current guidelines or risk 
stratification tools? Perhaps the current stratification tools do not reflect the detailed assessment 
process that goes into the HCP's decision regarding warfarin prescribing. This section explores 
factors that affect the HCP practice in maintaining the warfarin therapy at optimal levels or that 
deter the HCP from initiating therapy. The factors discussed include fear of the patient bleeding, 
fear of the patient falling, underestimating the patient's stroke risk, fear of patient 
noncompliance, fear of the patient developing cognitive decline, patient and HCP beliefs, the 
HCP's prescribing practices, and the time needed to manage patient care. 
Fear of Bleeding 
The first and most common reason that the HCP may not initiate warfarin therapy or may 
initiate suboptimal levels of warfarin therapy is the HCP' s fear that the patient will have a 
potential complication from a bleed. Researchers have clearly indicated that warfarin therapy is 
the best practice for prevention of strokes in the high-risk patient (Hart et al., 2007; Mant et al. , 
2007; van Walraven et al. , 2002). These researchers supported warfarin therapy despite the risk 
that the patient may haemorrhage because they found that the risk was lower for bleeding than 
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the risk ofthe patient experiencing a stroke. Hylek et al.'s (2007) research added to the 
discussion about risk of bleeding but presented a very different perspective to the findings 
presented in the "Research that Evaluates Warfarin Therapy" section of Chapter 2. Hylek et al. 's 
study focused on the risk of bleeding in persons who were over the age of 80 years with NV AF, 
and their research questioned if this cohort had been fairly represented in previously published 
research studies. Hylek et al. 's study included 472 patients who were started on warfarin between 
2001 and 2003 and were followed for one year. Of the 472 patients, 32% were greater than or 
equal to 80 years of age and 91% had at least one stroke risk factor (Hylek et al., 2007). Of the 
participants who were 80 years of age or older, the incidence of major haemorrhage was 13.1 %, 
while those under 80 years of age had an incidence of 4. 7% (Hylek et al., 2007). It is concerning 
that the risk ofbleeding in the 80 years of age or older cohort was over 2.5 times the rate ofthose 
patients under 80 (Hylek et al., 2007). Hylek et al. 's study adds validity to some HCPs' fear that 
their patients may experience a bleed while taking warfarin. These HCPs may initiate alternative 
therapy to warfarin for treatment of their patients who have NV AF. As valid as these fears 
maybe in some cases, HCPs should not allow these fear to overshadow the decision-making 
process, including the risk analysis, as many patients are still appropriate candidates for use of 
warfarin therapy. 
Fear of Falls 
The second reason an HCP may not initiate warfarin therapy is the HCP's fear that the 
patient will fall and suffer a subsequent bleed. As patients age, their balance and gait patterns 
may alter. Appreciating that older patients are at a higher risk for falls, Schumann and Ewigman 
(2007) acknowledged that a history of falls or a patient who is at risk of falls is a contraindication 
for anticoagulation therapy. Nevertheless, Tulner et al. (2010) drew a strong conclusion against 
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this fear. Tulner et al. identified that in one year a patient would have to fall 295 times to be 
considered a contraindication for warfarin administration. They further concluded that subdural 
haematomas and intracranial haemorrhages from a fall are uncommon and should not influence 
the HCP from prescribing warfarin therapy to eligible patients. 
According to the BC Warfarin Therapy guidelines (Guidelines and Protocols Advisory 
Committee, 201 0), falls are not identified on either "the absolute contraindication" list nor on the 
"some relative contraindication" list, which are highlighted in tables in the main part of the BC 
guideline. Table 2 (included in Figure C2 in Appendix C) in the guidelines document does, 
however, identify falls as a risk factor for bleeding complications from warfarin therapy 
(Guidelines and Protocols Advisory Committee, 2010, p. 4). This guideline leaves the decision to 
administer warfarin up to the HCP (Guidelines and Protocols Advisory Committee, 2010), but 
recommends the HCP weigh the risks ofbleeding against the benefit of the therapy. The HCP's 
interpretation of distinction between contraindications, risk factors, and his or her perception 
about how many falls classifies "falls" as a risk factor or contraindication that would prohibit 
warfarin therapy may affect the HCP's clinical judgment on whether or not warfarin therapy 
should be administered. 
Underestimating the Patient's Stroke Risk 
The third reason the HCP might not initiate warfarin therapy is because he or she may 
have underestimated the patient's risk for stroke. It is crucial to identify the best candidates to 
receive warfarin. Therefore, the decision to administer warfarin, with a known risk factor for a 
major bleed, does require thorough risk stratification. Doucet et al. 's (2008) prospective trial was 
conducted in four geriatric hospital settings. Doucet et al. followed 209 older inpatients (84. 7 +/-
7 years of age) with chronic AF for 3 months and examined the decision-making parameters that 
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the HCP used to determine whether the patient would receive aspirin or warfarin therapy. Doucet 
et al. found that in one third of all the patients thromboembolic risk was underestimated and 
physicians overestimated the risk of bleeding in half of all the patients. Using the CHADS2 test 
(BC Ministry of Health, 2009a) on high-risk patients, Doucet et al. calculated the theoretical risk 
of a thromboembolic event at 98% and the theoretical haemorrhagic risk at 17%, while 
physicians subjectively calculated the risk for these same patients to have a thromboembolic 
event at 65% and haemorrhagic risk at 38%. For 3 months following discharge from the hospital, 
each patient's prescription for warfarin or aspirin was left unchanged and the Doucet et al. found 
that there was no increase in patient outcomes including bleeding, death, or ischemic events. The 
limitation of this trial was that Doucet et al. included patients with prior valvuloplasties, which 
was not part of the inclusion criteria for this project. However, the findings are significant in 
terms of the decision-making process and outcomes. Additionally, current risk stratification tools 
may be too simplified to reflect the complexities of the patient profile. Despite risk stratification 
tools recommending the administration of warfarin, the HCP may chose to follow or not to 
follow this recommendation due to their in-depth holistic assessment. 
Fear of Patient Noncompliance 
The fourth reason the HCP may not initiate warfarin therapy is the fear the person will 
not take the drug as ordered, obtain routine INR testing, or maintain necessary lifestyle choices 
that do not interfere with the warfarin therapy. A subtrial within the W ASPO trial assessed 
patients with NV AF for medication compliance by using a Medication Event Monitoring 
System, which Rash et al. (2007) described as, 
[An] electrical system that is designed to compile the dosing histories of ambulatory 
patients prescribed oral medications. The system comprises two parts: a standard plastic 
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vial with threaded opening and a top for the vial that contains a micro-electric circuit that 
registers when the vial is opened and when it is closed. (p. 152) 
The medical compliance aspect of Rash et al. 's trial lasted four weeks and demonstrated that 
older persons were 96.4% compliant, with correct dosing. Rash et al. 's trial affirmed that older 
adults in their study were able to manage complex anticoagulant therapy independently. 
Although Rash et al. 's (2007) findings demonstrated that the older persons in their study 
had no problem maintaining compliance for the warfarin therapy regime, Waterman et al. (2004) 
presented another side to the question of whether the older person can strictly adhere to the 
medication regime. Waterman et al. found 23% of patients were out of range in their INR levels 
and patients who were 80 years of age or older had the most out-of-range INR results. The 
overall findings in Waterman et al. ' s study showed that 36% ofthe time INRs were out of range 
(lower than 1.8 and higher than 3.4) it was due to the patients ' noncompliance in following the 
medication regime. In Waterman et al. ' s study, noncompliance was due to consumption of 
vitamin K through dietary intake, alcohol consumption, misunderstanding around instructions 
about the dose to take, failure to fill or refill the prescription, or refusal to take the medication. 
Fear of the Patient Developing Cognitive Decline 
The fifth reason HCPs may not prescribe warfarin therapy or that warfarin therapy may 
be subtherapeutic is that older patients may have or be at risk of developing cognitive decline or 
has a cognitive deficit. In these cases, the HCP's lack of confidence in the patient's ability to 
manage his or her own therapy safely, combined with the HCP's inability to routinely monitor 
the patient, are realistic drawbacks for primary care providers. The Public Health Agency of 
Canada (2010) identified that 400,000 older persons were living with dementia and predicted that 
this number would double in 30 years. Patients taking warfarin and other medications need to be 
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competent to ensure safety of medication administration. Since cognitive decline and dementia is 
a progressive disease, it may not easily be recognized in the early stages. The commitment to 
completing ongoing competency assessments and fear that the patient may not be able to follow 
the warfarin therapy protocols may give HCPs pause for initiating the therapy in the first place 
(van Deelen, van den Bernt, Egberts, van't Hoff, & Maas, 2005). 
Patient and Health Care Practitioner Beliefs 
The sixth reason the HCP may not initiate warfarin therapy is that the patient and HCP 
may have a different values or beliefs on taking warfarin. Values related to the risk of bleeding, 
the risk of having a stroke, adherence to pharmaceutical regime, clinical guidelines, drug 
interactions, and the time and cost of monitoring the therapy can all play into the HCP's decision 
to initiate treatment or the patient's decision to accept or decline the therapy (Garcia-Alamino et 
al., 201 0). Hylek et al. 's (2007) trial demonstrated that the patient's belief around the benefit or 
safety of a drug could significantly alter therapeutic use of warfarin therapy. In Hylek et al. 's 
study 26% of the cohort who were 80 years of age or older discontinued taking warfarin within 
the first year after the study ended, and 81 % of patients who had stopped taking warfarin were 
due to the patient ' s and/or the HCP' s perceptions around safety concerns, bleeding, falls , 
nonadherence with drug monitoring, coagulopathy, and dermatologic concerns. In van Walraven 
et al. 's (2002) meta-analysis the opposite belief system was revealed; older persons in this study 
felt they would rather take warfarin therapy, comply to the medication regime, and risk having a 
bleed than not take the medication and risking having a stroke. Identifying patient and HCP 
beliefs around anticoagulation therapy can take time, as can highlighting areas of difference and 
desires to the approach to care. Some patients simply may not want warfarin therapy, and the 
HCP would have no choice but to accept the patient's wishes and provide an alternate approach 
to prevention, despite the HCP's good intention to provide the more therapeutic option of 
warfarin therapy. 
The Health Care Practitioner 's Prescribing Practices 
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The seventh factor that affects the prescribing practices of warfarin is the HCP's specialty 
and/or location of practice. Kellen (2004) and Halperin (2005) both identified that internists and 
cardiologists prescribed anticoagulation therapy at a much higher rate than family or general 
practitioners. Kellen furthered this differentiation by identifying that HCPs practicing in rural 
environments are less likely to anticoagulate their patient than urban HCPs. Perhaps this is due to 
factors that inhibit optimum use of the drugs, such as a lack of local facilities for INR testing or 
hospitals in the event that urgent care is needed. 
The Time Needed to Manage Patient Care 
The final reason that warfarin therapy may not be prescribed or managed 
subtherapeutically is the amount of time required to manage the medication protocols. The 
responsibilities and time for managing patients with NV AF can be extensive. Many HCPs simply 
do not have the time and resources to provide in-depth AF care on their own. Dhond et al. (2003) 
highlighted that many physicians find anticoagulation management time consuming and 
inconvenient. In fact, Cohen et al. 's study (as cited in Dhond et al., 2003) stated that 94% of 
physicians surveyed in the United Kingdom preferred that another care provider handle 
anticoagulation management. Time or lack thereof may be creating gaps in health care. 
Bajorek, Ogle, Duguid, Shenfield, and Krass's (2007) study examined how warfarin use 
could be improved. Bajorek et al. conducted group discussions and one-on-one interviews with 
49 key players in the healthcare system in Australia, including nurses, pharmacists, and general 
practitioners, along with 14 patients with AF who were over the age of65. The first key finding 
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from Bajorek et al. 's study was that both the HCP and the patient with AF found that it was 
difficult to obtain current, detailed information on AF and warfarin therapy. Patients in Bajorek 
et al. 's study identified that although they wanted detailed explanations, patients also wanted the 
information conveyed to them at a slower pace than they were provided by their HCP, so that 
they could absorb the information (Bajorek et al., 2007). Sadly, the patients in Bajorek et al. 's 
study felt abandoned by the HCP in their anticoagulation therapy and felt that they were 
responsible for their own learning. 
Summary 
In summary, this chapter presented findings of a literature review that evaluated warfarin 
therapy. The studies concluded that the administration of warfarin therapy was the best practice 
for the prevention of strokes in the high-risk older patient with NV AF. Despite warfarin therapy 
being identified as best practice, research was presented that identified that warfarin is highly 
underutilized or is managed subtherapeutically in the older population. Eight factors, including 
fear of the patient bleeding, fear of the patient falling, underestimating the patient's stroke risk, 
fear of patient noncompliance, fear of the patient developing cognitive decline, patient and HCP 
beliefs, HCP's prescribing practices, and the time needed to manage patient care, were discussed. 
The next chapter will consider these eight factors and will provide a discussion that addresses the 
role that FNPs could play to help optimize administration of warfarin therapy in primary care 
settings. 
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CHAPTER3 
IMPLICATIONS FOR NURSE PRACTITIONERS' PRACTICE 
This chapter considers the project's third subquestion: How can FNPs facilitate optimum 
care of the older person with NV AF and therapeutic administration of warfarin therapy? The 
administration of warfarin has been underutilized in many health care practices, and new 
approaches are needed to provide NV AF patients with a more consistent management of their 
condition. FNPs are members of interdisciplinary teams ofHCPs. By utilizing more NPs in the 
health care system, NV AF patients' access to health care could be increased. 
According to Pulcini, Jelic, Gul, and Lake (2010), NPs "represent a sleeping giant for 
healthcare systems worldwide" (p. 37), and I believe that BC would benefit by tapping into this 
resource. By increasing FNPs in primary health care, older patients may have increased access to 
care and may receive a more consistent approach to their health care and for their warfarin 
therapy. FNPs work autonomously and collaboratively with other HCPs in providing 
comprehensive primary care to persons with NV AF. Currently, there are over 1,990 NPs in 
Canada (Canadian Institute for Health Information, 2011a), of which 186 are in BC (College of 
Registered Nurses of British Columbia [CRNBC], 2011). In BC, FNPs care for patients "with 
common acute and chronic physical and mental diseases, disorders and conditions" (CRNBC, 
2009, p. 6). The FNPs scope of practice includes diagnosing patients, ordering and interpreting 
diagnostic tests, and prescribing medications (Canadian Nurses Association, as cited in Canadian 
Nurses Association, 2008). This chapter provides an expanded discussion outlining specific 
responsibilities that FNPs can assume to help optimize warfarin therapy. FNPs responsibilities 
discussed include providing increased access to general screening, completing physical health 
assessments and referrals, completing risk stratification tools, medication requirements and 
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screening for warfarin interactions, and completing mental health assessments. The chapter also 
discusses methods for increasing FNPs confidence in warfarin therapy, which includes reducing 
the FNP's fear of the patient having a bleed while on warfarin therapy, reducing the FNP's fear 
of the patient falling, and improving warfarin therapy compliance in the patient. Finally, this 
chapter ends by supporting the role ofFNPs as an interdisciplinary, collaborative team member. 
How Family Nurse Practitioners Can Optimize Warfarin Therapy 
General Screening Process 
The first way that FNPs can reduce suboptimal warfarin therapy is for FNPs to provide 
screening services to increase the number of older patients who are screened for AF. The 
decision to initiate warfarin therapy or not requires the HCP to have confidence in knowing the 
patient. The comprehensive patient data collection begins far before the prescription for warfarin 
therapy is ever written. In most cases, the initial data collection begins during the initial 
screening process that the HCP provides to all his or her patients. 
FNPs are trained to approach their patients holistically and to emphasize health 
promotion and disease prevention (CRNBC, 2009), so the current NP scope of practice supports 
the FNPs in initiating relevant screening processes. The screening process may be used within 
the FNP's office setting or FNPs may consider setting up a portable screening clinic that could 
offer increased access to screen a greater number of older persons within the community. 
Screening for AF need not be separate from the FNP's existing screening processes; FNPs 
typically utilize a general screening process to look for risk factors for common chronic 
conditions, which include risk factors for AF and stroke. 
If FNPs were to consistently approach prevention of risk factors, they could provide 
multiple patients benefits (BC Ministry of Health, 2008). Although people are living longer in 
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the 21st century, Gersh et al. (2005) stated we are a '"sicker population' having a higher 
prevalence of comorbid conditions including hypertension, diabetes, CHF [congestive heart 
failure]" (p. C7), and obesity. Importantly, these four comorbid conditions are not only risk 
factors for stroke but they are also risk factors for AF (Gersh et al., 2005). By increasing overall 
screening within the older population, early identification of AF may be achieved, which may 
support earlier implementation of therapies, thereby reducing the potential risks of leaving AF 
untreated. 
Completing Health Assessments and Referrals 
The second way that FNPs could help reduce suboptimal warfarin therapy involves FNPs 
providing comprehensive assessments to patients and identifying the appropriate candidates for 
warfarin therapy. FNPs have advanced training in patient health assessments and can complete 
and document detailed systematic assessments. If FNPs diagnoses a new arrhythmia while 
conducting an assessment, FNPs have the authority to complete specialist physician referrals for 
the patient (CRNBC, 2011 ). By facilitating a referral to the cardiologist, FNPs create access for 
the patient to specialized care. FNPs are also authorized to order (a) all laboratory tests as set out 
in the Medical Services Commission Payment Schedule (conditions apply, see document); 
(b) any diagnostic services listed in MSC Laboratory Medicine Payment Schedule or on the 
CRNBC 's Scope of Practice for Nurse Practitioners list; and (c) any imaging services, as long as 
it is on the list outlined within the CRNBC ' s (2011) Scope of Practice for Nurse Practitioners: 
Standards, Limits and Conditions document. To improve the efficiency of the patient's first 
meeting with the consulting specialist, FNPs would be able to order diagnostic tests such as an 
ECG, a bolter monitor, or laboratory screening in advance of the specialist meeting. The FNPs 
would also be able to interpret the results of the tests for patients, which may help reduce 
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potential anxiety for seeing a specialist. They could also provide clarification to the patient after 
the specialist visit if needed. FNPs would also be able to assess patients for any manifestations of 
AF and determine if the patients are stable or if they need to be transferred to an acute care 
facility. The comprehensive approach to care that FNPs offer provides comfort and reassurance :, 
; ,, 
to concerned patients (Thrasher & Pure-Stephenson, 2008). 
Risk Stratification 
FNPs are able to integrate their assessment data and assist in increasing utilization of 
warfarin therapy, by completing a risk stratification tool to determine the patient's level of risk 
for having a stroke. It is recommended that patients who meet the criteria to be anticoagulated 
based on a risk stratification tool such as the CHADS2 test be prescribed warfarin (BC Ministry 
of Health, 2009a). If the patient cannot tolerate warfarin due to side effects, allergies, or patient-
FNPs choice, the FNPs would then be available to provide alternative stroke prevention 
strategies such as aspirin therapy. To reduce the risk ofunderestimating the patient's 
thromboembolic risk, as was the case in Doucet et al. (2008) study, FNPs can ensure that the risk 
stratification tool is consistently utilized for every NV AF patient. FNPs can maintain a practice 
that is current and up to date, utilizing new guidelines and new risk stratification tools as they 
become available, which may offer more comprehensive screening process. Deplanque et al. 's 
(2004) study recognized that HCPs lacked up-to-date knowledge of pathophysiology and of 
current literature on trials and guidelines. FNPs who are motivated to stay current and up to date 
may consider networking with each other to ensure they are continuing to provide evidence-
based care. 
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Medication Requirements and Screeningfor Warfarin Interactions 
FNPs could provide pharmaceutical requirements for patients with NV AF and cross-
check for interactions with other medications or products that reduce the efficiency of warfarin 
therapy. It is within FNPs' scope of practice to write prescriptions for their patients. Drugs that 
the FNPs can prescribe are listed within the CRNBC (2009) Scope of Practice for Nurse 
Practitioners document in three categories: (a) "No Exceptions" drugs, which means the FNPs 
can prescribe the drug with no exceptions; (b) "C" category drugs, which means FNPs can 
prescribed the drug with continuation only restrictions; and (c) "0" category drugs, which means 
FNPs cannot prescribe the drug. Warfarin is a drug that falls under the AHFS 20:00 category 
Blood Formers and Coagulators and is considered a no-exception drug (CRNBC, 2011; S. Wade, 
personal communication, October 20, 2011 ). Therefore, FNPs can meet NV AF patients' 
pharmaceutical requirements for warfarin therapy. 
It is important to recognize that FNPs have the legal authority to write prescriptions for 
their patients, review previously ordered medications, and make alterations if needed because 
many patients over the age of 70 have multiple pharmaceutical requirements. The Canadian 
Institute for Health Information (20 11 b) confirmed this need, reporting that three in four older 
persons have at least one chronic condition. NV AF and strokes fall under the umbrella of chronic 
disease care and those with three or more chronic conditions are taking six or more medications 
(Canadian Institute for Health Information, 2011 b). Canadian Institute for Health Information 
(20 11 b) further identifies that older person with chronic conditions do not have their medications 
reviewed frequently enough, and FNPs are in a good position to be able to conduct medication 
reviews. The Public Health Agency of Canada (20 1 Ob) added a further concern and identified 
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that "50% of prescriptions are not taken properly" (p. 30) and "up to 20% of hospitalizations of 
people over the age of 50 are the result of problems with medications" (p. 31 ). 
Although all HCPs are working under time restrictions, FNPs have a reputation for 
spending more time with their patients in general (Horrocks, Anderson, & Salisbury, 2002), 
taking the time to review patient medications, and explaining the side effects of medications. By 
listening to questions, and sharing information with patients, FNPs provide patients with tools to 
promote better self-directed care (McCauley, Bixby, & Naylor, 2006) and improve patient 
confidence in understanding their prescribed medications. Patient education and therapeutic 
communication techniques may help to reduce hospitalizations and improve patient compliance 
to medication regimes. 
FNPs can manage warfarin therapy safely by conducting regular reviews of the patients' 
medications to ensure there are no drugs interactions with the warfarin therapy. Medications can 
also be included in the discussion between the FNPs and their patients. Over the counter drugs 
such as acetaminophen and aspirin are often not considered medications by the older persons as 
they do not require a prescription and, therefore, may be seen as unimportant (Gage et al. , 2001). 
Hylek et al. (2007) supported the need to review over-the-counter medications with patients, as 
they found 40% of the overall trial population combined aspirin with their warfarin therapy. The 
practice of combining warfarin with aspirin significantly increased the patient's risk of 
complications. Ofthe 26 haemorrhages seen in Hylek et al.'s study, 46% (12) were from the 
group that had combined aspirin and warfarin therapy. Medication interactions can have a 
significant negative impact on the patients. Therefore, it is important for FNPs to cross-check all 
medications. 
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FNPs can help prevent suboptimal warfarin therapy. This can be achieved by: 
(a) reviewing the Important Interactions with Warfarin patient resource (BC Ministry of Health, 
n.d.a) with the patient; (b) sharing information on naturopathic remedies such as herbal products 
(see Appendix F), which can significantly alter the level of warfarin; and (c) reviewing the 
Warfarin and Food: Guide for Patients (BC Ministry of Health, n.d.e), which identifies foods 
that containing vitamin K and can alter the therapeutic effect of warfarin. By providing the 
information at a slow pace and providing a written copy of the resources reviewed for the patient 
to take home, FNPs may increase the older person's understanding and retention of the 
information. 
Alcohol and smoking cigarettes are other products that can reduce the therapeutic benefit 
of warfarin therapy and put the patient at risk for complications (BC Ministry of Health, n.d.a). 
Small to moderate amounts of alcohol may not have a significant affect. However, heavy 
drinking and binge drinking can have serious consequences. Patients who drink heavily are at 
risk of: (a) falling more frequently, (b) eating poorly balanced diets, (c) forgetting to take their 
medications or taking the wrong dosage, (d) developing gastritis, (e) bleeding, and (f) forgetting 
to following through with INR testing (Baker et al., 2004). FNPs' strong communication and 
counselling skills (Charlton, Dearing, Berry, & Johnson, 2008; Conlon, 2010) may help support 
effective management of these patients and their warfarin therapy. FNPs may also be able to help 
facilitate a referral to an alcoholic detoxification program, smoking cessation program, or other 
support program if the patient desires. 
Completing Mental Competency Assessments 
FNPs can help reduce suboptimal warfarin therapy by providing mental competency 
assessments to evaluate their patient's ability for self-administration of medications. Assessment 
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of the patient' s mental competency takes time, cannot be rushed, and requires ongoing 
commitment to evaluating the patient' s status (Kellen, 2004). FNPs, with a nonjudgmental, 
trusting, and respectful manner, may present a discussion around mental health issues so that 
patients will feel comfortable discussing their life experience. Mental competency assessments 
are important when working with the elderly population because, as the patient ages, the mental 
health that once provided a stable foundation for coping with life can become overwhelmed by 
the changes resulting from the disease and aging process (BC Ministry of Health, 2008). 
By completing regular mental competency assessments FNPs may be able to improve the 
older patient's outcomes. Stress, anxiety, depression, and cognitive changes can all contribute to 
suboptimal warfarin therapy. To ensure that the patient is competent and is an appropriate 
candidate for warfarin therapy, the FNPs are able to conduct the Mini-Mental State Examination 
(BC Ministry ofHealth, n.d.c), the Montreal Cognitive Assessment tool (Nasreddine, 2011), and 
depression screening on a regular basis. Van Deelen et al. (2005) researched older persons with 
AF and cognitive impairment and showed that a mini-mental state examination score of less than 
23 was associated with suboptimal INR levels. FNPs have the skills to provide support to the 
older patients whose mental health may be changing. FNPs approach care with the awareness 
that health is interconnected with all aspects of the patient (McCauley et al. , 2006). FNPs possess 
a strong ability to create trusting relationships through good communication skills (McCauley et 
al., 2006), which may allow FNPs to discern a change in the patient' s mental status earlier than 
other HCPs. Shifts in cognition may cause the patient to no longer be competent or safely 
managing their warfarin therapy. The FNP's ability to assess cognitive functioning is essential 
for ensuring the patient can manage their own medication regime including warfarin therapy. 
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Communication 
Nurses have extensive training in communicating with a variety of patients, and the 
FNP' s scope of practice only adds to this skill set. Having good listening skills, not rushing 
patients, and providing enough time to answer all of the patients' questions helps FNPs to 
develop a therapeutic relationship with their patients (Charlton et al., 2008). FNPs can foster and 
empower patients and their families to become a partner in their own health care (BC Ministry of 
Health, 2008). It is important that FNPs be cognizant of all the factors that affect the decision-
making process for prescribing warfarin or withholding the drug treatment and question the 
validity of their decisions. In addition, open conversations that provide the patient the 
opportunity to express his or her wishes is important. Allocating enough time for sharing 
information with the patient so that his or her decision-making process comes from a well-
informed position is critical. An important observation in Bajorek et al. 's (2007) European study 
was that HCPs had a misconception that their colleagues were providing decision-making 
information to the patients, when in actuality the communication system was flawed, leading to 
patients receiving incomplete information. The assumption that another HCP was educating the 
patient is likely generalizable to other countries, including Canada. FNPs can ensure that they 
take on the responsibility for providing information to their own patients, which will reduce the 
chance that their patients do not fully understand the implications of warfarin therapy. 
Increasing Family Nurse Practitioners' Confidence in Warfarin Therapy 
Reducing the Fear of Bleeding 
Reducing the FNP's fear that the patient may experience a bleed may help to reduce 
suboptimal warfarin therapy. Strategies that focus on the reduction of bleeding risk factors such 
as the ongoing management of anticoagulation therapy, patient education, and prevention 
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activities (e.g., dietary monitoring) that have been previously discussed are crucial and can help 
FNPs have greater confidence in reducing the patient's likeliness of experiencing a bleed. As 
FNPs find a greater sense of confidence, they may find they increase the opportunity for more 
patients to receive warfarin therapy. Since the primary focus in NVAF patient care is to prevent a 
stroke, FNPs with strong communication skills can encourage and support the patient in being 
diligent with their warfarin administration and ensure regular INR testing practices. The most 
important role in primary prevention of strokes is try to ensure patients stay within the INR target 
range. Keeping the INR between 2 and 3 will also reduce the risk of a bleed that higher INR 
results can bring. 
Hylek et al. 's (2007) findings raised the concern for risk of bleeding in the elderly 
population; this research may be considered when the HCP is considering initiating warfarin 
therapy and determining the frequency ofiNR monitoring. Hylek et al. identified that 58% of 
major bleeds within their study occurred within the first 90 days of initiation of warfarin. 
Therefore, it is vitally important that the FNPs keep a vigilant watch on INR levels and watch for 
any signs of bleeding during this critical period. The fear that a patient might be at risk for a 
significant bleed related to the administration of warfarin is always at the forefront of the FNP's 
mind. Without the rig ours of monitoring the INR and keeping the INR level within the 
therapeutic range there will be a reduced benefit to initiating warfarin therapy. 
Portable prothrombin testing units may provide FNPs with a method to help patients 
maintain their INRs within therapeutic range. Portable prothrombin testing units or point-of-care 
(POC) devices provide increased access to INR levels. Garcia-Alamino et al.'s (2010) meta-
analysis looked at the effects of self-monitoring and self-management as compared to standard 
therapy. This study included 4, 723 patients from 18 trials and revealed that American patients 
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who conducted self-monitoring and self-management had a 50% reduction in thromboembolic 
events, 13% reduction in major haemorrhages, and a 36% reduction in all-cause mortality 
(Garcia-Alamino et al., 2010). Further, Garcia-Alamino et al. 's study found that self-monitoring 
reduced major haemorrhages significantly with little risk to the patient. Having instant INR result 
would allow FNPs to make immediate adjustments to the warfarin therapy either in the FNP's 
office or in the patient's home. Access for HCP to incorporate POC devices into their practice 
may foster more holistic patient care. 
FNPs are uniquely situated to provide such monitoring and evaluative services for NV AF 
patients. Any INR results that are not within the target zone will prompt the FNPs to follow up 
with patients to reassess possible contributing factors and determine if warfarin therapy should 
be continued. When FNPs initially starts the patient on warfarin therapy they may wish to 
allocate extended time for providing information to the patient. The goal is for their patients to 
understand all the implications of warfarin therapy and make informed decisions. FNPs can 
encourage the patient to be involved in understanding the INR values and diligent scheduling of 
the INR testing by using the Warfarin Therapy Management guidelines record (Guidelines and 
Protocols Advisory Committee, 2010). On this form, the patient can record their INR levels and 
any instructions for the warfarin dosing. To reduce the potential risk of anxiety related to the 
discovery of bleeding, FNPs can provide the patient with information about signs of bleeding. 
FNPs can further review the BC guideline Warfarin; A Guide for Patients (BC Ministry of 
Health, n.d.d), which identifies signs that could trigger the patient to contact the primary HCP. 
Reducing the Fear ofF ails 
It is important for FNPs to consider if the fear of the patient falling is a personal bias or if 
it is clinically reasonable. When considering personal bias, FNPs can look to Tulner et al. 's 
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(2010) study, which drew a strong conclusion against the fear that the patient will experience a 
bleed as a result of a fall while on warfarin therapy. Tulner et al. suggested that in one year a 
patient would have to fall 295 times for falling to be considered a contraindication for warfarin 
administration. Further, Tulner et al. identified that subdural haematomas and intracranial 
haemorrhages from a fall are uncommon and should not influence the practitioner from 
prescribing warfarin therapy to eligible patients. Reducing risk factors for falls around patients is 
important, and can help reduce the FNPs' fear of the patient falling. FNPs can gain further 
reassurance by completing detailed fall assessment tools, which might help provide FNPs with a 
more in-depth understanding of the individual patient's risk for falls. With detailed assessment 
data FNPs can make a more confident decision to administer or withhold warfarin therapy. 
Strategies to Reduce Noncompliance 
Increasing the patient's compliancy rate with medication regimes will reduce suboptimal 
warfarin therapy. FNPs may allocate additional time in their practice to provide their patients 
with information, counselling, and ongoing support for the management of warfarin therapy. By 
providing patients with comprehensive information, patients' compliance to therapy may 
improve. Older persons with NV AF require information around the diagnosis, the treatment 
options, and the risks if the diagnosis goes untreated. FNPs are highly trained and carry the 
knowledge to provide patients with information they will require to manage their own health. 
The amount of time that is required to meet the patient's initial and ongoing information needs 
can be significant. The Public Health Agency of Canada (20 1 0) identified a few reasons why 
extended time is needed for the educational process in the older adult population: 
Only one in eight adults (12%) over age 65 has adequate health literacy skills for many 
basic health-related decisions. Age is associated with lower health literacy of seniors due 
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to several factors , .. . slower processing of new information, higher incidence of mild 
cognitive impairment and dementia, and increased vision and hearing impairment. (p. 40) 
To meet patients' needs, the FNPs could consider offering information sessions for 
patients, patients' families, and the general public. This can be achieved through one-on-one 
sessions or by providing group inservices. One method FNPs can take under consideration is 
providing thorough and time-efficient health care for patients in a group medical visit. Group 
visits can offer a broader reach to multiple patients and can be incorporated into a 1- to 2-hour 
timeframe (McLaren, 2008). Patients benefit because they get to hear other patient's questions, 
concerns, and experiences, allowing for a greater grasp of knowledge. Most importantly, by 
making time in a group setting to share information and answer questions, FNPs may be able to 
avoid having patients feel "abandoned" (Bajorek et al., 2007, Discussion section, para. 3) and 
"alone" (Delegation of Responsibility for Warfarin Therapy section, para. 4) in their health care 
expenence. 
Family Nurse Practitioners as a Health Care Resource 
The final responsibility that FNPs can take on for reducing suboptimal warfarin therapy 
is to become an active member of an interdisciplinary collaborative health care team. Health care 
is changing, and new strategies need to be considered to meet the growing demand of the aging 
population, their complex needs, and the chronic diseases and conditions, including NV AF, that 
often effect members of this cohort. A solution to the growing health care gap is the increased 
utilization of FNPs to help fill the primary health care needs of the older population. FNPs offer 
not only the autonomous ability to function as independent primary care provider but they are 
also guided by their Scope of Practice (CRNBC, 2009) to maintain collaborative 
interdisciplinary relationships, which supports FNPs to endorse team member relationships. 
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When professional resources are unavailable, it may be important for society to reconsider how 
professional resources are utilized. 
Research studies support the use of FNPs for reducing time constraints and for meeting 
patient health care needs. Ducharme, Alder, Pelletier, Murray, and Tepper (2009) found that 
when FNPs were involved in patient care in emergency rooms, the benchmark wait time was 
reduced by 2.1 times and the length of stay was reduced by 48 .8%. The findings from McCauley 
et al. ' s (2006) study identified that FNPs improved patient outcomes, adherence to medications 
and treatment plans, patient's quality of life, and reduced hospitalization and overall health care 
costs. Finally, Thrasher and Pure-Stephenson' s (2008) study concluded that patients were highly 
satisfied with the FNP's care. These three studies are among many that have highlighted the 
significant role that the FNPs can play by having a more prominent role in providing primary 
health care for patients. 
Health Canada (2011) suggested that professional roles should be clarified and the scope 
of practice within each professional body should be utilized to its greatest capacity. By 
implementing a collaborative team-based model, professionals, including FNPs, can be more 
efficient in use of professional assets. By working with a collaborative approach, Health Canada 
(2007) stated, Canadians will have "better health outcomes, improved access to services, 
improved use of resources, and greater satisfaction for both patients and providers" (Preface 
section, para. 4) if professional teams are supported. By collaborating in teams, FNPs can 
maximize all the skills they have within their Scope of Practice (CRNBC, 2009) to optimize 
patient with NV AF and their health care needs, including warfarin therapy. By encouraging 
FNPs to take on the entire patient care needs or by providing support through a shared-care 
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approach with another HCP, patients who are at risk for complications from their NV AF may be 
managed optimally. 
Summary 
This chapter addressed the research subquestion: How can FNPs facilitate optimum care 
of the older person with NVAF and therapeutic administration of warfarin therapy? I described 
how FNPs can optimize warfarin therapy, discussed approaches for increasing FNPs' confidence 
in warfarin therapy, and last, I discussed the FNPs' role within an interdisciplinary collaborative 
health care team. The next chapter is the final chapter in this report and details the findings from 
the extensive literature review. 
CHAPTER4 
RECOMMENDATIONS AND CONCLUSION 
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The purpose of this project was to answer the primary question: Is the administration of 
warfarin the best practice for prevention of stroke in the person who is over the age of 70 years, 
who has NV AF, and who is at high risk for having a stroke? Findings from an extensive 
literature review were used to answer the project questions and expand the discussion throughout 
the project. Evidence presented within this project suggests that many patients who meet the 
criteria to have warfarin therapy initiated by the HCP have either not been prescribed warfarin or 
warfarin therapy has been managed suboptimally (Dhond et al. , 2003 ; Gattelari et al., 2008; 
Gladstone et al. , 2009; Tulner et al., 2010). The research studies reviewed for this project 
evaluated administrative practices of warfarin therapy, initiated by the HCP. Studies found that 
between 35.4% and 55% of the eligible participants over 75 years of age, were prescribed 
warfarin (Go et al. , 1999; see also Burton et al., 2001 ; Schumann & Ewigman, 2007). Gladstone 
et al. 's (2009) study identified that 7 5% of the patients who were taking warfarin were 
subtherapeutic. The studies reviewed for this project, highlighted that a significant number of 
patients had suboptimal warfarin therapy; these patients remained at risk of having a strokes. 
A number of factors were identified within the project that contributed to HCPs ' 
suboptimal management of warfarin therapy. These factors included underestimating the patient 
risk for having a stroke and requiring warfarin therapy, having risk stratification tools that do not 
reflect the patient profile, having a fear that the patient will bleed or have a fall and develop a 
subsequent bleed, and finally being fearful of the patient being noncompliant to medication 
regimes. The HCP' s job specialty, the HCP's beliefs (along with the patient's beliefs) about 
warfarin therapy, and a lack of time were identified as contributing factors that may affect 
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patients from either receiving optimal warfarin therapy or from receiving optimal management of 
the warfarin therapy by the HCP. 
FNPs bring a unique body of knowledge and skill that can provide for the comprehensive 
care for patients with AF. As such, FNPs can help facilitate optimal administration of warfarin. 
FNPs can help reduce suboptimal use of warfarin therapy by providing increased access to 
screening for NV AF, completing physical and cognitive assessments, completing risk 
stratification tools, completing referrals to specialist, and meeting patient requirements for 
pharmaceutical needs and laboratory tests and patient requirements for education. There are 
methods for reducing FNPs' fear of bleeding remains a concern in many FNPs' practice. To help 
alleviate some of these fears, FNPs can: (a) regularly monitor INRs to ensure that they are in 
therapeutic range, (b) increase supervision of the patient and INRs during the first 90 days, 
(c) complete regular assessments for interactions with all substances, and (d) educate the patient. 
By working within their full scope of practice FNPs may reduce strokes by improving 
therapeutic management of warfarin for the older persons with NV AF. 
Numerous research studies have been conducted on patients who have NV AF in an effort 
to understand best practice for prevention of thrombus and potential subsequent strokes. The 
research reviewed for this project suggests that the administration of warfarin therapy by the 
HCP is the best practice for the prevention of strokes in the high-risk person with NV AF who is 
over the age of 70 years. Warfarin significantly reduced strokes better than antiplatelets and 
remains best practice. HCPs should not avoid the initiation of warfarin therapy in their patients 
for fear of their patient bleeding as the studies examined found although the risk of a bleed is a 
real potential, the benefits of stroke prevention outweigh the low risk of a patient experiencing a 
bleed. 
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The older population is growing, and with this expansion comes the potential increase in 
persons who will experience NV AF. These future patients will require health care for their AF 
and possibly management of warfarin therapy. The implications of a patient having a stroke are 
vast and multifaceted. Stroke prevention strategies such as the administration of warfarin in the 
high-risk populations are important to consider. However, it is important to provide evidenced-
based care, and gaps still exist in the available research to date. Research and clinical trials that 
have been reviewed for this project have mainly focused on the 70- to 80-year-old cohort. The 
research has not been able to provide solid evidence that therapeutic practices for the older 
population (i.e., those over 80 years of age) will have the same outcome as those who are 
younger. It would be important to see further research conducted in primary care settings to see 
if warfarin continues to be the best choice for prevention of strokes in high-risk populations or if 
the risk of haemorrhage is higher in settings that are less controlled than hospital-based clinical 
trials. Research is continually exploring new practices and drug therapies for the management of 
patients with NVAF. It is pertinent that the HCP stays current in evolving best practice therapies. 
Recommendations 
With the research finding that this project has identified in mind, this project proposes 
three recommendations for improving the therapeutic management of patients with NVAF, who 
are high risk of stroke and require warfarin therapy: a recommendation for FNPs and the patient, 
for FNPs and the interdisciplinary team, and for FNPs and the Ministry of Health. 
The first recommendation relates to FNPs and the patient. FNPs can increase patient 
knowledge acquisition (individually and at the community level) and increase support around 
patient needs related to AF and warfarin therapy. This could be achieved by providing accessible 
office hours, phone services, counseling services, web-based services and/or group medical 
visits. 
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The second recommendation relates to FNPs and the interdisciplinary team. FNPs can 
foster increased peer and interdisciplinary knowledge of NV AF and warfarin therapy, including 
creating methods to share current clinical practice guidelines and the results of current research 
studies. FNPs can also collaborative with health care teams to develop strategies that focus on 
reducing the number of strokes in patients with NV AF. 
The third and last recommendation relates to FNPs and the Ministry of Health. FNPs can 
advocate to the Ministry for an increase in the numbers ofFNPs who work with patients with 
NV AF. FNPS can advocate to support work environments and jobs that are conducive to 
therapeutic management ofNV AF, which may optimize therapeutic management of warfarin. 
This may be achieved by FNPs advocating for the opening of AF clinics or creating funding to 
create new roles for FNPs to become NV AF consultants. FNPs can advocate to increase methods 
and technology for monitoring INR levels more therapeutically, such as supporting the use of 
Point-of-Care devices. 
Conclusion 
The most common arrhythmia seen in the general population is AF, and the incidence of 
AF continues to rise. Primary health care includes health promotion, illness prevention, holistic 
health assessment, diagnosis, and treatment, which are all services FNPs are uniquely qualified 
to provide (Canadian Nurses Association, 2005; Health Canada, 2006). To meet the growing 
demands ofNVAF patients, FNPs will have to overcome obstacles, but one that I must recognize 
is that FNPs in BC are a small cohort. There is much FNPs can offer for making improvements 
to the services that the health care system currently offers older persons with NVAF. With only 
186 NPs in BC (CRNBC, 2011), it will be important that all NPs work together to support a 
collective advancement in the profession. 
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FNPs are well situated to help reduce the risk of strokes in the 70 year old and older 
population with NVAF by optimizing warfarin therapy. I believe that ifFNPs are supported in 
their full scope of practice for providing care to patients with NV AF, that complications related 
to NV AF could be reduced. If Health Canada and other health professionals support FNPs, 
patients with NV AF could receive the benefits that this health care team member could provide. 
It is time for Canada to embrace the role of FNPs and reap the health care benefits this 
professional body has to offer. 
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APPENDIX A: ACC/AHA/ESC RISK STRATIFICATION TOOL 
Risk Category Recommended Therapy 
No risk factors Aspirin, 81 to 325 mg daily 
One moderate-risk factor Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0 
to 3.0, target 2.5) 
Any high-risk factor or more than 1 
moderate-risk factor 
Less Validated or Weaker 
Risk Factors 
Female gender 
Age 65 to 74 y 
Coronary artery disease 
Thyrotoxicosis 
Warfarin (INR 2.0 to 3.0, target 2.5)* 
Moderate-Risk Factors 
Age greater than or equal to 75 y 
Hypertension 
Heart failure 
LV ejection fraction 35% or less 
Diabetes mellitus 
High-Risk Factors 
Previous stroke, TIA or embolism 
Mitral stenosis 
Prosthetic heart valve* 
*If mechanical valve, target international normalized ratio (INR) greater than 2.5. 
INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack. 
Figure AI. Antithrombotic therapy for patients with atrial fibrillation. 
Note. From "ACC/AHA/ESC practice guidelines: ACC/AHA/ESC 2006 guidelines for the 
management of patients with atrial fibrillation- Executive Summary," by V. Fuster, L. E. 
Ryden, D . S. Cannom, H. J. Crijins, A. B. Curtis, K. A. Ellenbogen, ... S. Wann, 2006, 
Circulation, 114, p. 723, Table 10. 
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APPENDIX B: THE CHA2DS2VASc RISK STRATIFICATION EXPLANATION AND TOOL 
The explanation for the abbreviation CHA2DS2 V ASc that follows is taken from the 
ESC's "Guidelines for the Management of Atrial Fibrillation" (Camm et al., 2010): 
This risk factor-based approach for patients with non-valvular AF can also be expressed 
as an acronym, CHA2DS2 V ASc [congestive heart failure , hypertension, age 2: 7 5 
(doubled), diabetes, stroke (doubled), vascular disease, age 65-74, and sex category 
(female)]. This scheme is based on a point system in which 2 points are assigned for a 
history of stroke or TIA, or age 2: 7 5; and 1 point each is assigned for age 65-7 4 years, a 
history of hypertension, diabetes, recent cardiac failure, vascular disease (myocardial 
infarction, complex aortic plaque, and PAD, including prior revascularization, 
amputation due to PAD, or angiographic evidence of PAD, etc.), and female sex 
(Table 8). (p. 2382) 
Previous stroke,TIA. 
or systemic embolism 
At&e ~75 years 
Heart failure or moderate to 
severe LV systolic dysfunction 
(e.g. LV Ef ::S40%) 
Hypertension • D.iabetes mellitus 
Female sex • At&e 65-74 years 
Vascular cliseasea 
(b)Rfllc~ ••• ..,.... ............ ...... 
ICOl'fnaiJICIIm. wlthtM........,.CifAPSJ-VASc 
tfo1* l'ftiDCinUn score Is 9 Iince 111.., CtCIIItlibubt 1), f,or l polnes} 
Risk factor Scon! 
Congestive heart failure/LV dysfunction I 
Hypertension I 
At&e !:75 2 
Diabetes mellitus I 
Stroke{fiA/thrombo-embolism 2 
Vascular diseasea I 
At&e 65-74 I I 
Sex category (i.e. female sex) I 
Maximum score 9 
(c)A4u•eed .. ..-accwdlnatDc:HAaDSrVAScsa:n 
C~DS1·VASc Patients (n•7l29) AdJusted stroke 
K«e rate~) .. 
422 
2 1230 
3 1730 
171 8 
1159 
679 
294 
82 
14 15.2% 
Figure Bl. CHA2DS2VASc risk stratification tool. 
Note. From "Guidelines for the Management of Atrial Fibrillation," by Camm et al. , 2010, 
European Heart Journal, 31, p. 2382, Table 8. 
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APPENDIX C: CONTRAINDICATIONS FOR WARFARIN 
Absolute Contraindications Some Relative Contraindications 
• The presence of a severe or 
active bleeding diathesis 
• Non-adherence to medication and INA 
monitoring 
• Pregnancy2 (avoided at least during the first 
trimester and from about 2 to 4 weeks 
before delivery) 
• Allergy or intolerance to warfarin (consider 
warfarin alternative - Nicoumalone) 
Figure CJ. Contraindications for warfarin. 
• Uncontrolled hypertension 
{greater than 180/1 00 mm Hg) 
• Severe liver disease 
• Recent surgery and procedures involving 
the nervous system, spine or eye 
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Note. From Warfarin Therapy Management (p. 1), by the Guidelines and Protocols Advisory 
Committee, 2010, Victoria, BC, Canada: Queen's Printer. Copyright 2010 by the Guidelines and 
Protocols Advisory Committee. 
Risk Factor Category 
Age 
Time Period 
Cardiac 
Gastrointestinal 
Hematologic/Oncologic 
Neurologic 
Renal 
rauma 
Alcohol 
Medications 
Table 2: Risk Factors for Bleeding Complications 
of Anticoagulation Therapy1•8•18 
Specific Risk Factors 
> 70 years 
Within first year of warfarin treatment 
Uncontrolled hypertension, heart failure 
History of gastrointestinal haemorrhage, active peptic ulcer, 
hepatic insufficiency 
Thrombocytopenia, platelet dysfunction, coagulation defect, 
underlying malignancy 
History of stroke, cognitive or psychological impairment 
Renal insufficiency 
Recent trauma, history of falls 
Excessive alcohol intake 
Use of aspirin or other NSAIDs; Discontinuing medications that reduce INA; 
See Medication Interaction Table 
Adapted from: Warfarin Reversal Position Statement, Australasian Society of Thrombosis & Hematosls19 
Figure C2. Risk factors for bleeding complications of anticoagulation therapy. 
Note. From Warfarin Therapy Management (p. 4), by the Guidelines and Protocols Advisory 
Committee, 2010, Victoria, BC, Canada: Queen 's Printer. Copyright 2010 by the Guidelines and 
Protocols Advisory Committee. 
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APPENDIX D: LITERATURE REVIEW SEARCH PARAMETERS USED TO CONDUCT 
Parameter Description 
Time frame 
Indications 
Medication terms 
Limiters 
Key words 
LITERATURE REVIEW 
Parameter Specifications 
From 2001 through to 2011 
Atrial fibrillation, nonvalvular atrial fibrillation, arrhythmia 
and atria; cerebrovascular disease, and stroke. 
warfarin, aspirin; platelet aggregation inhibitors; platelet 
aggregation; and anticoagulant. 
Full text, peer reviewed 
Nurse practitioner, nurse; aged, aged 80 and over, age 70 years 
and over; frail elders, senior; elder abuse; multidisciplinary 
care team, multidisciplinary, collaborative care, collaboration, 
holistic; medications, pharmaceutical (s); medication 
compliance, medication regimen, self-medication; 
physiopathology; guidelines, practice guidelines, clinical 
practice guidelines; INR; education; adult education; 
prevention; evidence based, best practice; nursing practice, and 
evidence. 
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APPENDIX E: SEARCH ENGINE RESULTS -NUMBER OF HITS PER WORD 
Table El. 
Keywords Searches Per Database 
Database 
Key Words CINHAL MEDLINE COCHRANE 
nurse practitioner 654 752 288 
nurse 23940 18794 5571 
atrial fibrillation (AF) 918 4011 3477 
arrhythmia 591 3691 3522 
arrhythmia, atrial 12 
anticoagulant 163 2220 2107 
warfarin 574 2071 2044 
platelet aggretion inhibitors or 
404 0 0 
platelet aggregation inhibitors 
stroke 5101 17287 18860 
aspmn 1161 3912 7730 
international normalized ratio or 
206 995 696 
INR 
aged 37952 337875 250225 
aged 80 & over 37952 69849 2262 
over 70 558 2296 
frail elder 1269 7 0 
semor 1293 3028 1141 
elder abuse 877 
multidisciplinary 4561 0 1812 
multidisciplinary care team 3445 0 
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Database 
Key Words CINHAL MEDLINE COCHRANE 
collaborative or collaboration 6016 5345 4701 
holistic 1669 2717 309 
medications 2354 10784 25976 
pharmaceutical 3040 0 
pharmaceuticals 214 0 1481 
medication compliance 1429 809 343 
medication regimen 39 121 144 
physiopathology 13720 105959 2450 
self-medication 130 538 232 
guidelines 11135 30556 11472 
practice guidelines 6729 841 
clinical practice guidelines 253 841 649 
education 65573 81639 22602 
adult education 138 55 47 
prevention 53040 124505 40268 
evidence based 9713 16633 46 
best practice 986 1192 342 
nursing practice 7724 2155 248 
evidence 21186 129869 53221 
Note. Search date: July 2011. 
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Figure E 1. Flow Chart of Search Strategy 
Literature Search Strategy 
D 
Primar_y Source Non-Academic Source Reference Page Source 
Cumulated Index ofNursing Google Scholar Reference lists of the literature 
Allied Health Literature Go ogle cited were used to direct 
Medline Full Text Internet Search additional searches, and these 
Cochrane Database of findings were included within 
Systematic Reviews 
90 Single studies 
35 NP Practice 
51 AF/ Stroke/and 
Anticoagulation 
Therapy (i.e., 
Warfarin/ 
Dabigatran/ 
Clopidogrel/ 
Aspirin) 
4 Other: Theories 
on Aging, 
Geriatric 
Assessment, Falls, 
Homebound 
Seniors 
the overall literature review . 
D 
Initial Search : Total192 Resources 
These resources were divided into 5 Categories 
D 
13 Meta-analysis/ 10 Guidelines: 53 
Systematic 1 Provincial Discussion 
Review/Cochrane 9 National Papers 
Review Guidelines 13 NP/ 
6 Meta-analysis/ Nursing 
Systematic Review 40AF 
7 Cochrane Review 
D 
78 Resources were utilized in this project. 
These resources were divided into 4 Categories 
D 
26 Internet 
Resources: 
3 Heart/Stoke 
13 Ministry: 
4NP 
3 Collaboration 
6 Population 
Statistics on age 
and health 
4 Pathophysiology 
7 Nursing 
Association 
43 Atrial Fibrillation 10 Guidelines and 15NP Practice 10 Government 
Pathophysiology Practice Protocols Statistics and 
Anticoagulation Charters 
Therapy: Warfarin 
Stroke 
APPENDIX F: HERBAL PRODUCTS THAT SIGNIFICANTLY ALTER THE LEVEL OF 
WARFARIN 
Herbal Products 
Ferverfew 
Ginger 
Ginkgo 
Horse chestnut 
Pau d'arco 
Vitamin e 
Green tea 
Ubiquinone (coenzyme Q 1 0) 
Dnashen 
Dong qua 
Fenugreek 
Garlic 
Saw palmetto 
Alfalfa 
Ginseng 
St. John's wort 
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